Market evolution: Artificial joints (CN 902131) — 2015–2025

Introduction

This report examines the European Union's external trade in artificial joints for orthopaedic purposes (Customs code 902131) over the period 2015–2025. Over this decade, the EU consolidated its position as a major global producer and net exporter in this high-value medical device segment. Export values more than doubled, rising from approximately €2.75 billion to €5.77 billion, while imports grew more moderately from €1.33 billion to €2.39 billion. The resulting trade surplus widened from €1.42 billion to €3.38 billion. Behind these headline figures lie significant structural shifts in production capacity, geographic specialisation, and trade concentration dynamics that are analysed in the sections below.

General overview of EU trade in CN 902131

1. A surge in production capacity underpins the EU's export boom

1.1. EU production volumes grew fivefold over the decade

The most striking structural change in the EU artificial joints market is the dramatic expansion of production. According to PRODCOM data, the number of items produced within the EU rose from 5.4 million units in the first period to 27 million units in the last — a fivefold (+400%) increase. In value terms, production grew from €900 million to nearly €4.38 billion (+386.7%). This expansion is consistent with the global trend of ageing populations driving demand for joint replacement surgery, as well as the EU's positioning as a manufacturing hub for premium orthopaedic implants.

1.2. Export growth outpaced import growth by a wide margin

The production surge translated directly into a reorientation of trade flows. Exports grew by +109.7% in value (from €2.75 billion to €5.77 billion), while imports increased by +79.6% (from €1.33 billion to €2.39 billion). In quantitative terms, export volumes rose +67.7% (from 3,379 to 5,667 tonnes) versus +55.1% for imports (from 2,591 to 4,019 tonnes). This differential reflects the EU's growing export propensity, which rose from 27.3% to 124.7% — meaning that by the end of the period, exports substantially exceeded domestic production value, likely reflecting re-exports and the growing integration of EU plants into global supply chains.

1.3. Price premiums confirm the EU's position in the high-end segment

A notable feature of EU trade is the persistent price differential between exports and imports. Average export unit prices ranged from €611,000 to €1,193,000 per tonne over the period, compared to €474,000 to €595,000 per tonne for imports. This premium — roughly 50–70% above import prices — suggests that EU producers primarily serve the premium orthopaedic implant segment, while imports cater to lower-cost segments or serve as intermediate inputs. The export price rose +25.0% over the decade, versus +15.8% for imports, indicating growing EU specialisation in higher-value products.

2. Geographic concentration is declining, but key partners still dominate

2.1. The United States remains the EU's largest bilateral partner

The United States is by far the EU's most important non-EU trade partner for artificial joints, both as an export destination and an import source. In 2025, the EU exported €2.44 billion worth of artificial joints to the US (up +91.6% from €1.27 billion in 2015) and imported €799 million (up +23.1% from €649 million). The US alone accounts for over 42% of EU exports and roughly 33% of EU imports in this product. This deep bilateral relationship reflects both the scale of the US orthopaedic market and the cross-investment by major multinational device manufacturers (e.g., Johnson & Johnson, Zimmer Biomet, Stryker) operating plants on both sides of the Atlantic.

2.2. Switzerland has become a major and fast-growing import source

Switzerland emerged as the second-largest import source, with values rising from €406 million to €1.03 billion (+154.8%) — making it almost as large as the US by 2025. This is likely linked to the presence of major orthopaedic manufacturers (e.g., Medacta, Mathys) headquartered or producing in Switzerland, which then export finished devices into the EU single market. On the export side, Switzerland also grew significantly (+148.6%), reaching €559 million.

2.3. Emerging partners are gaining share, while trade concentration is easing

The Herfindahl-Hirschman Index (HHI) for both imports and exports declined over the period — by −9.0% for imports (from 3,480 to 3,168) and −10.5% for exports (from 2,446 to 2,189). This indicates a modest but meaningful diversification of trade partners. Several emerging markets recorded very strong growth in EU exports:

These shifts suggest that EU manufacturers are expanding their footprint into Asia-Pacific and other growth markets, though the US and UK remain the dominant export destinations.

2.4. The United Kingdom's post-Brexit trajectory shows trade resilience

Trade with the United Kingdom has grown substantially since Brexit, with exports more than doubling (+157.1%) and imports rising +88.3%. This suggests that the medical devices sector — often characterised by inelastic demand and strong regulatory alignment — has been less affected by new trade frictions than other sectors. The UK remains the EU's second-largest export market for artificial joints.

3. A few EU Member States dominate production and trade, revealing wide internal disparities

3.1. Ireland and the Netherlands are the EU's leading specialised exporters

The specialisation analysis reveals a stark geographic concentration of expertise within the EU. In 2025, Ireland held a Revealed Symmetric Comparative Advantage (RSCA) of 0.74 and an RCA of 6.81 — by far the highest in the EU. The Netherlands followed with an RSCA of 0.41 and RCA of 2.36. These two countries, alongside Belgium and Austria, account for the lion's share of EU production and exports.

The Netherlands' role is particularly notable: it recorded the largest absolute increase in export value among EU members, growing from €336 million to €1.96 billion (+485.1%). Ireland's exports rose from €544 million to €1.89 billion (+247.4%). These figures suggest that both countries host significant manufacturing and/or distribution hub activities for global orthopaedic device firms.

3.2. Germany's trade profile tells a story of shifting intra-EU production patterns

Germany recorded a puzzling dynamic: its imports from non-EU countries fell by −44.2% (from €405 million to €226 million), while exports grew only modestly (+16.1%). This contrasts with the explosive growth in the Netherlands and Ireland. One possible explanation is a redistribution of production and logistics within the EU, with firms consolidating manufacturing in the Netherlands and Ireland — possibly driven by tax incentives, logistics infrastructure, or workforce availability — while Germany's role as a direct importer and re-exporter has diminished accordingly.

3.3. Most Central and Eastern European members have virtually no specialisation

At the other end of the spectrum, countries such as Hungary (RSCA: −0.999), Lithuania (RSCA: −0.986), and Slovakia (RSCA: −0.983) show near-zero specialisation in artificial joints. Their production shares are negligible (0.001% or less). This confirms that the orthopaedic devices industry remains heavily concentrated in Western Europe, likely reflecting the sector's requirements for advanced R&D capabilities, specialised labour, and proximity to major hospital networks and regulatory expertise.

3.4. The EU's net import reliance has collapsed, confirming structural self-sufficiency

Perhaps the most striking indicator of the EU's evolving position is its net import reliance. In 2015, the EU had a positive net import reliance of +22.2%, indicating moderate dependence on external supply. By 2025, this figure had swung to −219.4%, reflecting the massive expansion of the trade surplus. This shift means the EU is now a major net supplier of artificial joints to the rest of the world, comfortably exceeding its own import needs.

The trade intensity indicator rising above 100% further confirms that the EU's engagement in this market is now disproportionately driven by exports relative to its own consumption — a hallmark of a globally competitive export industry.

Conclusion

Over the 2015–2025 period, the EU has transformed its artificial joints sector from a moderately import-dependent market into a powerhouse of global orthopaedic device exports. This transformation was driven by a fivefold expansion in domestic production capacity and the consolidation of manufacturing expertise in a handful of Western European Member States — principally Ireland, the Netherlands, Belgium, and Germany. The EU's trade surplus in this product nearly tripled, reaching €3.38 billion by 2025, while its net import reliance swung from +22% to −219%.

Despite this overall strength, the market exhibits notable vulnerabilities. Geographic concentration among trade partners has eased only slightly, with the United States and Switzerland still accounting for a dominant share of both imports and exports. Volatility in key partner relationships — with coefficients of variation ranging from 11% to 75% depending on the partner — and periodic price shocks (notably around 2019 for Australia, India, and Switzerland) indicate that supply chain risks persist. Meanwhile, the near-total absence of specialisation in Central and Eastern European EU members points to significant intra-EU disparities that may warrant attention from an industrial policy perspective.